Fusogenic membrane glycoproteins (FMG) are a family of viral genes that, when expressed in tumour cells, trigger extensive cell to cell fusion and subsequent cell death. Gene therapy approaches using FMG are also potentially immunogenic, since syncitia generated ex vivo can be therapeutic as antitumour vaccines in murine models. This study has addressed the mechanisms responsible for the immunogenicity of FMG-mediated cell death, and its applicability to human immune priming. We show that fusion of human Mel888 melanoma cells following transfection with FMG can reverse the suppressive effects of Mel888 on dendritic cells (DC) phenotype, and potentiate IL-12 production by DC on activation in a cell contact-dependent manner. DC loaded with fusing, but not intact, tumour cells primed a naive, tumour-specific cytotoxic T-cell response, which was MHC class I-restricted and associated with production of high levels of IFNg and, later, IL-5. Fusing cells were an effective source of antigen for DC cross-priming and presentation of the melanoma-specific antigen gp100 to a specific T-cell clone. These data show, in a human system, that FMG represent an immunogenic, as well as cytotoxic, gene therapy for cancer, reversing the inhibitory effects of tumour cells on DC to potentiate IL-12 production and naive T-cell priming.
Introduction
Fusogenic membrane glycoproteins (FMG) are a novel class of viral genes for the gene therapy of cancer. FMG expression in tumour cells leads to massive cell to cell fusion, formation of large multinucleated syncitia, and eventual cell death.
1 FMG tested to date include a truncated form of the gibbon ape leukaemia retrovirus envelope gene (GALV), measles F and H, and the vesicular stomatitis virus G glycoprotein (VSV-G). GALV and F/H, encoded by adenoviral and lentiviral vectors, have shown therapeutic activity in xenograft models, thus supporting the use of these genes as direct cytotoxic agents.
1,2 FMG-mediated cell death occurs by predominantly nonapoptotic pathways with mitochondrial failure and ATP depletion. 3, 4 As syncitial formation progresses, there is nuclear fusion, premature chromosome condensation and autophagic degeneration, accompanied by release of cellular vesicles reminiscent of exosomes (syncitiosomes). 3 With current vectors, the therapeutic potential of a gene therapy that is only cytotoxic to the transfected cell, without any effect on surrounding cells, is likely to be limited. During FMG-mediated cell death, recruitment of untransfected cells into growing syncitia causes a local bystander effect, which is significantly more potent than that of the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir system. 1 In addition, FMG may generate a systemic, immune-mediated bystander effect, since they trigger nonapoptotic cell death and induce heat shock proteins (HSP), 1, 3 which can act as nonspecific stimulants of innate immunity, and chaperone tumourassociated antigens (TAA) for T-cell priming. 5 Furthermore, FMG are foreign viral genes, encoding proteins that may offer additional adjuvant support during immune activation.
Data supporting the potential immunogenicity of FMG-mediated cell death has previously been reported. In a human in vitro system, exosome-like vesicles secreted during cell fusion (syncitiosomes) effectively loaded dendritic cells (DC) for crosspresentation of a melanoma TAA. 3 Furthermore, murine DC loaded with fusing tumour cells expressing ovalbumin (OVA) successfully stimulated OT1 cells, showing that FMGmediated cell fusion facilitates crosspriming by DC of specific antigens onto MHC class I for presentation to reactive T cells. 6 The only FMG whose immunogenicity has been tested to date in vivo is VSV-G, since other FMGs (GALV and F/H) are unable to fuse mouse cells, precluding their use in immunocompetent murine systems. In a mouse melanoma model, tumour cells triggered to fuse ex vivo were a potent vaccine against a subsequent live tumour challenge or early established disease, particularly if the vaccine comprised both allogeneic and autologous tumour cells. 6 Hence, there is evidence to support the immunogenicity of FMG gene therapy, although its application to human cancer, and the mechanisms underlying immune activation, remain largely unclear.
This study has addressed the effects of FMG-mediated tumour cell fusion on DC phenotype and function, and determined whether DC loaded with fusing tumour cells are able to prime a naive human cytotoxic T-cell (CTL) response. The results show that GALV-mediated cell fusion not only reverses the suppressive effects of human melanoma Mel888 cells on DC maturation but can potentiate IL-12 production by activated DC. IL-12 potentiation is contact-dependent, and also seen on expression of VSV-G in tumour cell/DC cocultures. DC loaded with fusing tumour cells were able to present the melanoma-specific antigen gp100 to reactive T cells, and prime a naive, tumour-specific cytotoxic response against Mel888 in vitro. These data support the potential of FMG as an immunogenic, as well as cytotoxic, gene therapy for human malignancy, able to activate DC and provide an effective source of antigens for immune priming.
Results

Syncytia formation
To test the immunological effects of FMG-mediated cell fusion in human tumour cells, Mel888 melanoma cells were first transfected with GALV as previously described. 3 As expected, after 48 h, GALV expression induced the formation of large multinucleated syncytia which are absent in normal growing cells (Figure 1 ).
Effect of normal and fusing Mel888 cells on DC phenotype
The interaction between tumour cells and professional antigen-presenting cells, particularly DC, is central to immune priming following gene therapy-mediated tumour cell death. 7 Therefore, to address the immunological consequences of GALV-mediated human tumour cell fusion in vitro, the effect of normal and fusing Mel888 cells on DC phenotypic activation was first tested. DC were cocultured with fusing or nonfusing tumour cells in the presence or absence of LPS/IFN-g, and DC maturation measured by expression of MHC Class II, CD80, CD86, CD83, CD58, CD40 and CD1a. As a maturation factor, LPS/IFN-g was chosen as the most potent of a range of factors tested for human DC phenotypic activation and IL-12 production. Initial experiments showed that Mel888 transfected with control, empty plasmid were similar to untransfected Mel888 in their effects on DC phenotype following coculture (data not shown).
The addition of nonfusing or fusing Mel888 cells alone had little effect on immature DC phenotype. Figure 2a shows the surface expression of the costimulatory molecule CD86 after incubation with normal or fusing Mel888 cells. A slight increase in median fluorescence intensity (MFI) was observed in the presence of untransfected or FMG-expressing tumour cells in this donor. However, this change was not consistent in all donors tested, and no significant changes were observed in other immature DC markers after coculture with fusing or nonfusing Mel888 cells in the absence of DC activation (data not shown). In contrast, Mel888 cells significantly affected the ability of DC to upregulate CD86 in response to LPS/IFN-g. Untransfected whole tumour cells inhibited LPS/IFN-g-induced DC CD86 upregulation (Figure 2b -pink histogram), but this inhibition was consistently released when Mel888 cells were undergoing fusion following transfection with GALV (blue histogram). This finding was highly reproducible between donors (n46). The same pattern of inhibition of DC activation in the presence of Mel888 cells, and its release on tumour cell fusion, was also seen for CD40 and CD58 (pink vs blue histograms, Figure 2c and d, respectively), but no consistent changes were seen in MHC class II, CD80, CD83 and CD1a on LPS/IFN-gactivated DC in the presence of nonfusing or fusing Mel888 (data not shown). Although changes in DC phenotype did not apply to all maturation markers, these data suggest that FMG-mediated cell fusion can potentially release the immunosuppressive properties of Mel888 on DC activation. Mel888 are known to secrete IL-10, which can block DC maturation and IL-12 production, and skew DC towards a tolerogenic phenotype. 8, 9 We therefore explored IL-10 as a potential mechanism for the suppressive effects of Mel888 on DC. However, fusion of Mel888 cells did not affect levels of IL-10 in the supernatant over the time course of these experiments, and blocking of IL-10 with soluble receptor had no effect on the phenotype of activated DC in the presence of fusing or nonfusing tumour cells (data not shown). Hence, IL-10 is not responsible for the inhibition of phenotypic activation on LPS/IFN-g-activated DC by Mel888, or its release on FMG-mediated tumour cell fusion.
Effect of intact and fusing Mel888 cells on DC Th1 cytokine production
To further examine the functional consequences of tumour cell fusion on DC, we next tested production of the key Th1 cytokine IL-12 by DC in the presence of nonfusing or fusing Mel888 cells. As shown in Figure 3a , untreated DC produced very low levels of IL-12p40 and p70, which, as expected, were upregulated on DC stimulation with LPS/IFN-g. This pattern of IL-12 production was, however, significantly different on coculture of DC with tumour cells. Whereas the addition of nonfusing Mel888 abrogated IL-12 production by LPS/IFN-g-activated DC, fusing tumour cells actually potentiated IL-12 secretion, with both p40 and p70 levels increased compared to those obtained after treatment with LPS/IFN-g alone. A similar pattern of suppression by tumour cells, with release of inhibition when tumour cells were fusing, was also seen for an alternative Th1 cytokine, TNF-a (Figure 3b ), although in this case no potentiation of cytokine release on tumour cell fusion was apparent. We then tested whether LPS/IFN-gmediated DC IL-12 p70 production was similarly potentiated by tumour cells expressing VSV-G, which has been shown to be immunogenic in murine model systems. 6 VSV-G-mediated cell fusion, unlike GALV, can be controlled via the acidity of the cell culture medium; 6 a transient drop in pH triggers fusion, which is absent under normal culture conditions. Therefore, for VSV-G, we were also able to test the effect of FMG expression with or without generation of syncitia. As shown in Figure 3c , VSV-G expression by Mel888 also potentiated IL-12 production by activated DC. This effect was seen with or without syncitia, but was greater when tumour cell fusion had been triggered by low pH. Hence, the presence of FMG-transfected Mel888 potentiates IL-12 production by DC on activation, most effectively in the presence of fusion, providing a potential mechanism for effective priming of a Th1-sustained cytotoxic T-cell antitumour response.
Potentiation of IL-12p70 by DC with cell fusion is cell-cell contact dependent
To explore potential mechanisms behind the potentiation of IL-12 from DC cultured in the presence of fusing tumour cells, we performed transwell experiments to test whether this effect required cell to cell contact, or was induced by a soluble factor. Control experiments were set up as for Figure 3a , while in transwell experiments DC in the upper chamber were separated from fusing Mel888 cells in the lower chamber by a 0.4 mm filter. As previously, a 3:1 ratio of tumour cells to DC was used, and DC were treated with LPS/IFN-g. Cell culture supernatants were collected after 24 h and the levels of Fusogenic membrane glycoprotein-mediated immune priming F Errington et al IL-12p70 were determined by ELISA. Figure 4 shows that DC alone produce between 500 and 1000 pg/ml of IL12p70 after treatment with LPS/IFN-g in both the control and transwell conditions. When DC were in contact with fusing Mel888 cells, there was a 2-3-fold increase in IL12p70 production, consistent with the data shown in Figure 3a . However, when DC were physically separated from fusing Mel888 cells by the transwell filter, potentiation of IL-12p70 production was abolished. Therefore, enhanced production of IL-12p70 by DC in the presence of fusing tumour cells was dependent on direct cell to cell contact.
Priming of tumour-specific CTL by DC loaded with intact or fusing Mel888
These effects of tumour cell fusion on DC phenotype and cytokine production may influence their interaction with naive T cells, 10 potentially facilitating priming by DC of an antitumour cytotoxic T-cell response. Therefore, the ability of fusing vs nonfusing tumour cell-loaded DC to prime a human naive T-cell response against Mel888 was determined. DC were loaded with control/nonfusing or GALV-transfected/fusing Mel888 cells and activated with LPS/IFN-g; autologous PBMC were then cocultured with tumour cell-loaded DC, and further restimulated weekly ( Â 2) to test expansion and priming of any cytotoxic antitumour T-cell response.
To monitor PBMC proliferation during naive priming, the number of viable cells present each week was determined by trypan blue exclusion. PBMCs stimulated with DC loaded with nonfusing Mel888 cells did not undergo significant T-cell expansion, yielding only 1-10 Â 10 6 total cells at the end of the 3-week culture. This poor yield limited our ability to perform cytotoxicity studies using these effectors, and is consistent with the immunosuppressive effects of Mel888 illustrated in Figures 2 and 3 . In contrast, PBMCs stimulated with DC loaded with fusing Mel888 cells yielded significantly more effector cells, on average 60-70 Â 10 6 cells after 3 weeks of culture. This differential effect on T-cell expansion during priming by DC loaded with fusing or nonfusing tumour cells is shown for two representative donors in Figure 5a .
CTL activity against Mel888 and other melanoma cell lines was determined after 3 weeks of culture by standard chromium release assays. CTL generated using fusing Mel888-loaded DC were able to efficiently kill Mel888 targets, with up to 90% lysis observed; Figure 5b shows patterns of target killing in two typical donors. No significant cytotoxicity against other melanoma cell lines was seen. In some donors, enough CTL were generated after stimulation with nonfusing Mel888-loaded DC to perform limited cytotoxicity assays against Mel888. CTL from these cultures did show some cytotoxicity against Mel888 targets, although always 42-fold less than CTL generated using fusing cells in the same donor (data not shown). CTL killing was MHC class I restricted, as shown by a significant reduction in target cell lysis on addition of a pan-class I blocking antibody, but not of an isotype control (Figure 5c ).
These data show that fusing Mel888 cells are more effective at loading DC with antigen for priming of a naive CTL response, than suppressive nonfusing cells. The cytotoxic response is MHC class I restricted and tumour specific, with no significant crossreactivity against other melanoma cell lines.
Cytokine accumulation in CTL culture supernatants
The production of cytokines in CTL cultures generated using nonfusing or fusing Mel888-loaded DC was investigated to determine whether cell fusion polarized towards a Th1 or Th2 immune response. Figure 6a shows that CTL cultures stimulated with DC loaded with fusing Mel888 cells produced Th1-associated IFN-g (up to 25 000 pg/ml) at levels greater than cultures primed with nonfusing cells. This IFN-g was secreted by both CD4 and CD8T cell subsets, as demonstrated by intracellular cytokine staining at weeks 1 and 2 ( Figure  6b and c) . The only other cytokine tested whose levels changed significantly during culture was IL-5 (classically a Th2 cytokine), which accumulated late during T-cell priming in cultures stimulated by fusing cell-loaded DC (Figure 6d ). IL-12 was not seen at these time points in these cultures, most likely due to DC exhaustion and/or rapid depletion by proliferating T cells, 11 and no IL-4 was detected. IL-10 levels correlated with the presence of IL-10-secreting Mel888 cells during initial priming and restimulation, thus preventing assessment of IL-10 production by other cell types in the cultures (DC, T cells; data not shown). Hence, although cytokine levels in these CTL cultures did not follow a complete Th1/Th2 partition, there were significant differences in cultures primed with fusing and nonfusing cells, reflecting their different efficiencies in CTL priming. High level IFN-g production in these cultures would be consistent with in vivo development of a Th1 response following vaccination with FMG-expressing tumour cells.
Crosspresentation of a defined melanoma TAA by DC loaded with fusing Mel888 tumour cells Effective, specific CTL priming by DC loaded with fusing, but not intact, Mel888 cells suggests a response directed against multiple potential TAA expressed by the tumour. Since these antigens remain undefined and may not all be tumour-related (e.g., some may be alloantigens), we wished to ensure that a candidate melanomaspecific TAA within this antigen array could be crosspresented by DC loaded with fusing tumour cells. Such crosspriming has previously been reported for a Fusogenic membrane glycoprotein-mediated immune priming F Errington et al murine model antigen, 6 and from exosome-like vesicles (syncitiosomes) released on fusion, 3 but not for a human melanoma antigen derived from fusing tumour cells as used in the current study. We used gp100 as a defined HLA-A2-restricted melanoma TAA, which is expressed by Mel888, but cannot be presented directly from tumour cell to reactive T cells because Mel888 is A2À. 3 Hence, any activation of specific T cells on tumour cell/DC coculture must represent crosspresentation of the antigen by the DC. As shown in Figure 7 , coculture of HLA-A2+ (but not A2À) DC with fusing, but not intact, Mel888 cells led to activation of the gp100 T cell clone, confirming effective crosspresentation of a relevant melanoma TAA when fusing tumour cells are used as the source of antigen for loading of APC. This suggests that the antigen repertoire accessed by DC cocultured with fusing tumour cells includes relevant TAA to support priming of an effective antitumour CTL response.
Discussion
FMG are a promising novel approach to the gene therapy of cancer. Their expression in tumour cells is directly cytotoxic, leading to formation of large syncitia which become metabolically depleted over time, leading to mitochondrial failure and ultimate cell death. 4 As cell to cell fusion progresses, surrounding nontransfected cells are recruited into expanding syncitia, generating a significant local bystander effect. 1 In addition, FMG expression and tumour cell cytotoxicity is potentially immunogenic. In a murine melanoma model, tumour cells undergoing FMG-mediated cell fusion ex vivo were an effective vaccine when administered to animals with early established disease. 6 Possible mechanisms underlying the immunogenicity of FMG-mediated cell fusion include the induction of immune 'danger signals' (such as HSP) associated with nonapoptotic cell death, the release of TAA in exosome-like vesicles (syncitiosomes) Fusogenic membrane glycoprotein-mediated immune priming F Errington et al for effective delivery to antigen-presenting cells such as DC, and the nonspecific adjuvant effect due to expression of a foreign viral protein in tumour cells. 1, 3 The data reported here further explores potential interactions between DC and tumour cells undergoing FMG-mediated cell fusion, and examines the ability of fusing cells to load DC for priming of a naive, human CTL response. GALV-transfected, fusing human Mel888 melanoma cells were chosen because (i) there is some evidence that under these conditions Mel888 can effectively provide specific TAA for crosspriming of DC, 3 and (ii) untreated Mel888 cells are potentially suppressive to immune priming, in part due to their secretion of IL-10. Hence, these systems allow testing of whether FMG-mediated cell fusion affects interactions between suppressive human melanoma cells and the immune system during priming of a potentially therapeutic response.
Experiments coculturing tumour cells with DC showed that nonfusing Mel888 cells inhibited upregulation of the DC maturation markers CD86, CD40 and CD58 following stimulation with LPS/IFN-g, but that this inhibition was released when tumour cells were fusing following transfection with GALV ( Figure 2 ). There were no major effects of Mel888 cells on immature DC phenotype in the absence of activation signals, and no consistent changes in other DC maturation markers (MHC class II, CD80, CD83 and CD1a). Tumour cells are known to exert a range of suppressive effects on DC via secretion of cytokines such as IL-10, IL-6, VEGF and M-CSF, or via cell surface interactions. [12] [13] [14] [15] Although Mel888 secrete IL10, the suppression of DC activation was not IL-10 mediated in these experiments, since levels of secretion were similar from fusing and nonfusing tumour cells, and the addition of soluble IL-10 blocking receptors was unable to lift this suppression. 
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The restriction of DC phenotypic changes to some (CD86, CD40, CD58) but not all (MHC class II, CD80, CD83, CD1a) activation markers is intriguing, although its precise functional consequences are currently unclear. Nevertheless, the reversal of restricted DC phenotypic activation in the presence of tumour cells by fusion following GALV transfection may facilitate effective T-cell priming against antigens delivered to DC from tumour cells.
In addition to the effects on DC activation phenotype shown in Figure 2 , Mel888 cells had a major effect on Th1 cytokine production by DC stimulated with LPS/IFN-g. In the presence of whole, nonfusing tumour cells, DC secreted significantly lower levels of IL-12 on activation ( Figure 3a) ; this is consistent with previous data on the suppressive effects of tumour cell supernatants on IL-12 from DC. 16 In contrast, coculture of fusing tumour cells with activated DC actually potentiated production of both IL-12p40 and p70 compared to cultures of stimulated DC alone. This pattern of cytokine suppression in the presence of intact Mel888 with release of inhibition on tumour cell fusion (although without potentiation) was also seen for TNF-a (Figure 3b) .
Regarding enhanced DC IL-12 secretion on coculture with fusing tumour cells, it is worth noting that (i) it occurred despite the similar phenotypes of LPS/IFNgactivated DC alone, and LPS/IFNg-activated DC cocultured with fusing Mel888 (Figure 2 ), (ii) it was not evident without addition of LPS/IFNg to cocultures and (iii) it was also seen on DC cocultured with VSV-Gexpressing Mel888. Interestingly for VSV-G, FMG expression by tumour cells potentiated DC IL-12 even in the absence of fusion (i.e. at normal pH). However, p70 levels increased still further when Mel888 was triggered to fuse by a transient drop in pH, suggesting that both VSV-G expression and progression of syncitia contribute to activation of DC (Figure 3c ). While in previously reported murine melanoma studies the immunogenicity Fusogenic membrane glycoprotein-mediated immune priming F Errington et al of VSV-G in vivo was entirely dependent on cell fusion with expression alone inadequate for immune priming, 6 we have seen protection against more immunogenic models than B16 following vaccination with nonfusogenic VSV-G-expressing tumour cells (manuscript in preparation). Hence, expression of an FMG is of itself potentially immunogenic, with triggering of cell fusion and subsequent death augmenting the immune response still further.
In our study, the consequences of DC coculture with fusing/nonfusing tumour cells were greater for cytokine production, including IL-12, than for phenotypic change on DC. Previous studies have also shown that DC activation measured by phenotypic maturation and IL-12 production do not always correlate, since monocytederived DC treated with tumour culture supernatant upregulate surface expression of a range of activation markers, but lack the capacity to produce IL-12. 16 Hence, different signalling pathways are likely to control various aspects of DC maturation (phenotype, IL-12/TNF-a secretion), allowing differential responses to specific environments, including interaction with FMG-expressing tumour cells. This highlights the need to examine a wide profile of marker expression and cytokine production in different DC populations when assessing their functional behaviour on interaction with tumour cells, which may impact on the subsequent activation or tolerization of T-cell responses. 9 The high levels of IL-12 and TNF-a secreted by DC cocultured with fusing tumour cells could facilitate antitumour immune priming in vivo. In particular, IL-12 favours differentiation of Th1 helper cells and activates NK cells, providing a link between the innate and adaptive immune response. 17 DC transfected to secrete high levels of IL-12 have been used successfully in a range of antitumour strategies, [18] [19] [20] supporting a role for local DC-derived IL-12 in tumour immunotherapy.
When activated DC were separated from fusing tumour cells by a filter in a transwell chamber, the potentiation of IL-12 production was lost (Figure 4) . Hence, enhanced IL-12 production by DC is dependent on direct contact with tumour cells expressing FMG rather than a soluble factor. One candidate diffusible factor was HSP70, which is expressed in some cells fusing following FMG transfection 1 and accumulates in exosome-like vesicles (syncitiosomes) secreted by Mel888 during fusion.
3 HSP70 can act as a nonspecific adjuvant for DC activation, 21, 22 as well as chaperoning antigens for crosspriming to T cells. 23 Interestingly, however, HSP70 was not upregulated following GALV expression in Mel888 (data not shown) and syncitiosomes, although small enough to pass through the transwell filter, were incapable of activating DC for IL-12 production in this system. We are currently investigating alternative mechanisms for the cell contact-dependent potentiation of IL-12 production by DC with FMG-mediated cell fusion. One possibility is direct engagement of the FMG expressed on tumour cells with toll-like receptors (TLR) on DC, thus triggering IL-12 secretion. TLR mediate the pattern recognition by DC of microbial proteins, DNA motifs, HSP and other ligands central to the initiation of the innate immune response. 24 Specifically TLR4, which is expressed by monocyte-derived DC, is involved in the innate immune response to the fusion protein of respiratory syncitial virus. 25 However, our experiments thus far using TLR4-blocking antibodies and characterizing TLR signalling pathways in DC have not supported a role for TLR4 in DC activation by FMG-expressing tumour cells. Nevertheless, TLR remain potential candidates as mediators of immune activation by FMG tumour gene therapy.
Effective priming of a CTL antitumour response requires delivery of TAA to DC for uptake and crosspriming, with effective activation of reactive T cells. One potential advantage of using whole tumour cells as a source of TAA (rather than specific epitopes) is the range of potential, undefined antigens they express. Therefore, we tested whether fusion of tumour cells could enhance their ability to load DC with multiple antigens for priming of a human, tumour-specific naive CTL response. By priming and restimulating autologous T cells with DC loaded with fusing tumour cells, we were able to show effective naive priming and MHC class I-dependent cytotoxicity against Mel888 targets ( Figure  5 ), which was greater than when intact tumour cells were used to load DC. Furthermore, we found that a defined, relevant melanoma-associated TAA (gp100) is a potential component of the cells' antigenic mix, since gp100 was successfully crosspresented to specific T cells by DC loaded with fusing, but not nonfusing, cells (Figure 7) . We are currently testing whether A2+ CTL primed by DC loaded with GALV-transfected Mel888 are cytotoxic against T2 targets pulsed with gp100, or epitopes derived from other melanoma TAA. Preliminary experiments have not found any significant killing against distinct epitopes, suggesting that the cytotoxicity seen in Figure 5 is directed at multiple targets rather than focused on any single, defined antigen.
The accumulation of high levels of IFN-g in CTL cultures (Figure 6a ), which originates from both CD4 and CD8T cell effector subsets (Figure 6b, c) , implies generation of a Th1 response during naive cell priming by DC loaded with fusing tumour cells, which may enhance the efficacy of T-cell immunity following FMGmediated cell killing in vivo. The accumulation of IL-5 in the third week of T-cell priming (at lower levels than IFN-g, Figure 6d ) is consistent with a role for IL-5 during Figure 7 Crosspresentation of the melanoma tumour-associated antigen gp100 by DC loaded with fusing Mel888. To measure specific crosspresentation of a defined TAA, HLA-A2+ or -A2À DC were cocultured with fusing or nonfusing A2À Mel888 cells, followed by addition of T cells specific for a gp100 epitope presented in the context of HLA-A2. T-cell activation was determined by ELISA for GMCSF. Peptide-pulsed A2+ and A2À DC are included as positive and negative controls, respectively.
Fusogenic membrane glycoprotein-mediated immune priming F Errington et al induction of CTL, [26] [27] [28] while no IL-4 was detected and IL-10 correlated with the presence of Mel-888 cells at time points of priming and restimulation. We are currently analysing in more detail the T-cell phenotype and cytokine profile of these cultures to further investigate the effects of both fusing and nonfusing tumour cells on proliferation of specific T-cell subsets, including potentially suppressive regulatory cells.
Cell to cell fusion has been proposed as part of alternative immunotherapy approaches to cancer, including direct fusion between tumour cells and DC to generate hybrids expressing all TAA encoded by the tumour cell, within an APC incorporating all the antigenprocessing and presentation capabilities of the DC. [29] [30] [31] [32] Fusion in these studies has been achieved using polyethylene glycol (PEG) or electrofusion techniques. We have previously shown that FMG-mediated fusion between mouse tumour cells and DC generates more potent hybrids than PEG fusion, 33 confirming that fusion secondary to FMG expression is distinct and highly immunogenic. In the human Mel888/DC cocultures described here, we cannot formally distinguish between DC that have taken up tumour antigen, and the formation of DC/tumour cell hybrids, both of which may facilitate TAA crosspresentation and T-cell priming. Ongoing studies are addressing the relative immunogenicity of isolated FMG-expressing tumour cell/DC hybrids and the cocultures described here to inform development of optimal clinical FMG immunotherapy strategies.
In summary, we have shown that FMG expression and fusion of human tumour cells is potentially immunogenic, providing an effective antigen source in an appropriate context for priming of a naive antitumour CTL response. FMG expression by tumour cells has functional consequence on coculture with DC, reversing inhibitory effects of whole tumour cells on DC phenotype, and potentiating IL-12 cytokine production by DC when activating stimuli are present. These findings support the use of FMG as an immunogenic as well as cytotoxic gene therapy for cancer.
Materials and methods
Cell culture and transfections
Mel888, Mel-624, SK-30 and Mewo cells were grown in DMEM (Gibco BRL, Paisley, UK) supplemented with 10% (v/v) FCS (Harlan Sera-Labs, Crawley Down, UK) and 1% (v/v) L-glutamine (Gibco BRL). All cell lines were routinely tested for mycoplasma and found to be free of infection.
Immature DC were generated from human peripheral blood mononuclear cells (PBMCs), according to protocols previously published. 34, 35 Briefly, monocytes were selected by adherence onto plastic dishes for 1 h 30 min. Lymphocytes and other nonadherent cells were removed and monocytes were cultured in RPMI 1640 supplemented with 10% FCS and 1% L-glutamine (complete media, CM) containing 800 U/ml GMCSF (Schering-Plough, Cork, Ireland) and 0.05 mg/ml IL-4 (R+D Systems, Abingdon, UK) for 5-6 days. DC maturation was induced by addition of 250 ng/ml LPS (Sigma, Dorset, UK) and 1000 U/ml IFN-g (R+D Systems).
To generate syncitia in Mel888, cells were transfected with 1-2 mg of plasmid DNA encoding a hyperfusogenic mutant of the GALV envelope, 36 or fusogenic VSV-G, using the Effectene lipid reagent kit (Qiagen, Crawley, UK), according to the manufacturer's instructions. 1, 6 Tumour cell/DC coculture 1-5 Â 10 5 DC per condition and tumour cells were cocultured at a 1:3 ratio in CM containing GMCSF and IL-4. For DC plus fusing Mel888 cocultures, the Mel888 cells were transfected with GALV or VSV-G 48 h prior to coculture set-up. After 7 h, cocultures were either left untreated or stimulated with LPS/IFN-g for a further 16-20 h. Tumour cells and DC were harvested by gentle scraping and pelleted by centrifugation for flow cytometry. Cell free supernatants from cultures were aliquoted and stored at À801C.
Flow cytometry
Anti-human HLA-DR-PE, CD80-PE, CD86-PE, CD83-PE, CD40-PE, CD58-PE and CD1a-PE antibodies were used for DC phenotype. For CD80, CD86, CD83, CD40, CD58 and CD1a, DC were identified in the mixed DC/tumour cell population by initial gating on HLA-DR-FITCpositive cells (Mel888 is class II negative). All flow cytometry was performed using a FACSCalibur (Becton Dickinson, Hertfordshire, UK). For intracellular cytokine staining, T-cell cultures were treated with 10 mg/ml brefeldin A (Sigma) for 5 h, stained for human CD4 or CD8, and fixed in 1% PFA. Subsequently, cells were permeabilized using 0.3% saponin and stained with goat anti-human IFN-g prior to acquisition. All antibodies were obtained from BD Bioscience-Pharmingen, Oxford, UK.
Cytokine detection
Levels of IL-10, IL-12 (p40 and p70), TNF-a, IL-5, IL-4 and IFN-g in tissue culture supernatant were measured by ELISA using matched paired antibodies (all from BD Biosciences-Pharmingen except TNF-a from Biosource, Nivelles, Belgium) according to the manufacturer's instructions.
Generation of tumour-specific CTL
RPMI 1640 supplemented with 7.5% v/v FCS, 1% v/v L-glutamine, 1% v/v nonessential amino acids (Gibco BRL), 1% v/v sodium pyruvate (Gibco BRL), 1% v/v hepes (Gibco BRL) and 20 mM 2-b mercaptoethanol (CTL media) was used in all CTL cultures. Immature DC (HLA-A2+ or A2À) were loaded with tumour antigens by coculture with GALV-transfected fusing, or untransfected Mel888 HLA-A2À melanoma tumour cells, at a 1:3 ratio as described above. After 7 h, the DC were matured by addition of 250 ng/ml LPS and 1000 U/ml IFN-g overnight. Tumour-loaded DC were irradiated (30 Gy) and subsequently mixed with autologous PBMCs at a 1:10-1:30 ratio. In total, 5 ng/ml IL-7 (R+D systems) was added to cultures from day 1; 30U/ml IL-2 (R+D systems) was added on day 3 only. T cells were restimulated twice at weekly intervals, each time with tumour cell-loaded DC. At 21 days, cells were harvested and either used immediately in cytotoxicity studies or frozen down at 5 Â 10 6 cells/ml in FCS containing 10% DMSO. Cytotoxicity of CTL was measured using a standard 4 h Cr 51 release assay. Briefly, tumour cell targets were labelled with 100 mCi Cr 51 for 1 h, washed three times in CM and cocultured with CTL at different effector:target ratios. To reduce background/nonspecific killing, the same number of unlabelled K562 cells as target cells was added to each condition. After 4 h, cells were spun down and 50 ml of supernatant was transferred to scintillation plates (Packard Biosciences, Groningen, The Netherlands). To test MHC class I restriction, Mel888 cells were preincubated with a pan-class I blocking antibody (Dako, Cambridgeshire, UK) or Isotype control (Biocarta, Hamburg, Germany) at 50 mg/ml for 1 h prior to coculture with CTL. 6 human gp100/HLA-A2-specific T cells, which recognize a specific peptide epitope from gp100 in the context of HLA-A2 MHC Class I, 3 were added per well and GMCSF released by the CTL was assayed 48 h later.
Transwell cell separation experiments
Filters (0.4 mm) in transwell plates (Corning, Schiphol Rijk, The Netherlands) were used to separate DC from nonfusing or fusing Mel888 cells. Tumour cells were placed in the bottom of the tissue culture well to allow adherence and extended syncytia formation, while DC were placed in the top of the transwell system. DC and tumour cells were used at a 1:3 ratio, respectively, and LPS/IFN-g was added to appropriate wells 6-7 h after initial coculture. Supernatants were collected the following day and levels of IL-12p70 determined by ELISA.
